A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma

Study Status

Open to Enrollment

Study Description

This clinical trial is for men and women with relapsed or refractory lymphoma or multiple myeloma.

The treatments used to treat relapsed/refractory lymphomas and myeloma do not always work well, or they may only work for a short period of time. New treatments are therefore needed.

This study tests a new combination of drugs, romidepsin and lenalidomide, that are already FDA-approved for treating certain kinds of blood cancers. Romidepsin is an IV infusion. Lenalidomide is a pill taken by mouth. Both of these drugs by themselves have been shown to be effective in treating lymphoma and myeloma. The use of these drugs combined, however, is not FDA-approved and is therefore experimental.

The study has two parts. The first part is a Phase Ib study. In this part of the study, the researchers will determine what the best dose of each drug is when they are given together. Groups of up to 3 participants will receive specific doses of lenalidomide and romidepsin. If the side effects are not too serious, the next group of participants will receive a higher dose of one or both of the drugs.

The second part of the study is called a Phase IIa study. Groups of up to 15 participants with specific types of lymphoma or multiple myeloma will be studied using the doses of each drug determined in the Phase 1b portion to be safe. This part of the study will help determine whether the combination of the drugs is effective in treating lymphoma and myeloma.

Treatment Plan

Treatment cycles are 28 days. Participants will receive romidepsin via infusion on days 1, 8 and 15 of each cycle. Lenalidomide will be taken by mouth daily for 21 days of each cycle. Participants may continue to receive treatment as long as they are responding to therapy and not experiencing unexpected side effects. 

Disease Status and/or Stage

Relapsed or Refractory Lymphoma and Multiple Myeloma


Memorial Sloan-Kettering Cancer Center

Key Eligibility

  • Men and women age 18 and older
  • Diagnosed with lymphoma or multiple myeloma
    • For Phase IIa portion: must have B-cell lymphoma, T-cell lymphoma or multiple myeloma
    • Hodgkin lymphoma eligible for both phases
  • Relapsed or refractory disease after at least 1 systemic therapy
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Jia Ruan, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page